Handelsbanken Fonder AB Purchases 600 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Handelsbanken Fonder AB grew its position in Exact Sciences Co. (NASDAQ:EXAS) by 1.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,200 shares of the medical research company’s stock after acquiring an additional 600 shares during the quarter. Handelsbanken Fonder AB’s holdings in Exact Sciences were worth $2,765,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of EXAS. Huntington National Bank lifted its position in shares of Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after buying an additional 352 shares during the period. RPg Family Wealth Advisory LLC bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $35,000. Vestor Capital LLC bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $46,000. Finally, Asset Planning Inc bought a new position in shares of Exact Sciences during the 4th quarter worth approximately $40,000. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Up 4.1 %

Shares of Exact Sciences stock opened at $51.28 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The business has a fifty day simple moving average of $54.72 and a 200 day simple moving average of $60.00. The stock has a market cap of $9.53 billion, a PE ratio of -9.21 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million during the quarter, compared to analysts’ expectations of $701.45 million. Research analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.

Analyst Ratings Changes

EXAS has been the subject of several research analyst reports. TD Cowen lifted their price objective on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Piper Sandler cut their price objective on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Jefferies Financial Group lifted their price objective on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Barclays cut their price objective on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences has an average rating of “Moderate Buy” and a consensus target price of $72.24.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.